Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Umberto Vitolo, Alessandra Rossi, Pier Luigi Zinzani, Claudio Agostinelli, Pier Giuseppe Pelicci, Saveria Mazzara, Giovanna Motta, Valentina Tabanelli, Federica Melle, Myriam Alcalay, Corrado Tarella, Francesco Bertolini, Paolo Falvo, Stefano Fiori, Beatrice Casadei, Elena Baiardi, Stefano Pileri, Stefania Orecchioni, Enrico Derenzini, Angelica Calleri, Chiara Corsini
Publikováno v:
Leukemia
Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 levels, especially in the case of double hit (
Autor:
Natalia Voronina, Aurélie Ernst, Marc Zapatka, Gino Cioffi, Jill S. Barnholtz-Sloan, Andreas von Deimling, David T.W. Jones, Marina Ryzhova, Christian Aichmüller, Stefan M. Pfister, Thorsten Kolb, Andrey Korshunov, Martin Sill, Jan Gronych, Jonas Frisén
Publikováno v:
Oncogene
Adult pilocytic astrocytomas (PAs) have been regarded as indistinguishable from pediatric PAs in terms of genome-wide expression and methylation patterns. It has been unclear whether adult PAs arise early in life and remain asymptomatic until adultho
Autor:
Kasper Adelborg, Dóra Körmendiné Farkas, Mads Okkels Birk Lorenzen, Henrik Toft Sørensen, Jens Sundbøll
Publikováno v:
British Journal of Cancer
Lorenzen, M O B, Farkas, D K, Adelborg, K, Sundbøll, J & Sørensen, H T 2020, ' Syncope as a sign of occult cancers : a population-based cohort study ', British Journal of Cancer, vol. 122, no. 4, pp. 595-600 . https://doi.org/10.1038/s41416-019-0692-2
Lorenzen, M O B, Farkas, D K, Adelborg, K, Sundbøll, J & Sørensen, H T 2020, ' Syncope as a sign of occult cancers : a population-based cohort study ', British Journal of Cancer, vol. 122, no. 4, pp. 595-600 . https://doi.org/10.1038/s41416-019-0692-2
Background We examined if syncope was a marker of an occult cancer by comparing the risk in patients with a syncope episode with that of the general population. Methods Using Danish population-based medical registries, we identified all patients diag
Autor:
Sum-Yin Chan, To-Wai Leung, Chi-Chung Tong, Ka-On Lam, John M. Nicholls, Sik-Kwan Chan, Victor Ho-Fun Lee, Mai-Yee Luk, Ka-Chun Tsang, Dora L.W. Kwong, Cheuk-Wai Choi, Anne Wing-Mui Lee, Tsz-Him So, Pek-Lan Khong
Publikováno v:
British Journal of Cancer
Background Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) in endemic regions may have undetectable plasma EBV DNA. Methods We prospectively recruited 518 patients with non-metastatic NPC and measured their pre-treatment plasma EBV
Publikováno v:
British Journal of Cancer
Background Combinations of inflammatory markers are used as prognostic scores in cancer patients with cachexia. We investigated whether they could also be used to prioritise patients attending primary care with unexpected weight loss for cancer inves
Autor:
Buwen Yao, Xiaolin Ji, Jiang-feng You, Fang Mei, Rui Wu, Xinyang Li, Fei Pei, Yan Liu, Mengxue Zhang
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
The screening of non-small cell lung cancer (NSCLC) tumors for anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements is important because of the dramatically favorable therapy response to ALK inhibitor. However, the exact mechanism o
Autor:
Philip George, Yvette Hoade, Sahra Ali, Simon Watt, Varun Mehra, Catherine Cargo, Fergus Jack, Paul Evans, Tiziana Fanelli, William J. Tapper, Alastair Whiteway, Gabriela Sciuccati, Iwo Pieniak, Jamie Cavenagh, Emma Das-Gupta, Andres Virchis, Nicole Naumann, Kavita Patel, Rowena Thomas-Dewing, Patrick Thornton, Kris Zegocki, Louise Wallis, Charlotte Grimley, Gonzalo Carreño-Tarragona, Peter Forsyth, Andreas Reiter, Nicholas C.P. Cross, Laura Munro, Kaljit Bhuller, Andrew S Duncombe, Andrew Chase, Barbara J. Bain, Mohamad Jawhar, Johannes Lübke, Ali Rismani, Sonja Burgstaller
Publikováno v:
Leukemia
Cross, N C P, Hoade, Y, Tapper, W J, Carreno-tarragona, G, Fanelli, T, Jawhar, M, Naumann, N, Pieniak, I, Lübke, J, Ali, S, Bhuller, K, Burgstaller, S, Cargo, C, Cavenagh, J, Duncombe, A S, Das-gupta, E, Evans, P, Forsyth, P, George, P, Grimley, C, Jack, F, Munro, L, Mehra, V, Patel, K, Rismani, A, Sciuccati, G, Thomas-dewing, R, Thornton, P, Virchis, A, Watt, S, Wallis, L, Whiteway, A, Zegocki, K, Bain, B J, Reiter, A & Chase, A 2018, ' Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia ', Leukemia . https://doi.org/10.1038/s41375-018-0342-3
Cross, N C P, Hoade, Y, Tapper, W J, Carreno-tarragona, G, Fanelli, T, Jawhar, M, Naumann, N, Pieniak, I, Lübke, J, Ali, S, Bhuller, K, Burgstaller, S, Cargo, C, Cavenagh, J, Duncombe, A S, Das-gupta, E, Evans, P, Forsyth, P, George, P, Grimley, C, Jack, F, Munro, L, Mehra, V, Patel, K, Rismani, A, Sciuccati, G, Thomas-dewing, R, Thornton, P, Virchis, A, Watt, S, Wallis, L, Whiteway, A, Zegocki, K, Bain, B J, Reiter, A & Chase, A 2018, ' Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia ', Leukemia . https://doi.org/10.1038/s41375-018-0342-3
Determining the underlying cause of persistent eosinophilia is important for effective clinical management but remains a diagnostic challenge in many cases. We identified STAT5B N642H, an established oncogenic mutation, in 27/1715 (1.6%) cases referr
Autor:
Asher Chanan-Khan, Olga Samoilova, Charles Phelps, Michelle Mahler, Javier Loscertales, Dirceu Villa Villa, Ann Janssens, Andre Goy, M. Salman, Simon Rule, Claes Karlsson, Miguel A. Pavlovsky, Graeme Fraser, Angela Howes, Alexander Pristupa, Steven Sun, Marie-Sarah Dilhuydy, Abraham Avigdor, Paula Cramer, Panagiotis Panagiotidis, Nancy L. Bartlett, Sriram Balasubramanian, Jiří Mayer, Fatih Demirkan, R. Santucci Silva, Sebastian Grosicki, Halyna Pylypenko, Michael Hallek
Publikováno v:
Leukemia
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Ov
Autor:
Paul Kerbs, Philipp A. Greif, Wolfgang Hiddemann, Michel Sadelain, Marion Subklewe, Tobias Herold, Fabiana Perna, Samuel H. Berman, Stephanie Schneider, Sascha Haubner, Christina Krupka, Thomas Köhnke, Christian Augsberger, Felix S. Lichtenegger, X. Liu, Karsten Spiekermann, Christian Schmidt, Klaus H. Metzeler, Frauke M. Schnorfeil
Publikováno v:
Leukemia
Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-specific target antigens and clonal heterogeneity, leading to unwanted on-target off-leukemia toxicity and risk of relapse from minor clones. We hypothesize that
Autor:
Audrey Duquette, Vincent A. Miller, Aly-Khan A. Lalani, Toni K. Choueiri, Siraj M. Ali, A. Ari Hakimi, Stephanie A. Wankowicz, Lauren Young, Jeffrey S. Ross, Sabina Signoretti, Sumanta K. Pal, Russell Madison, Dominick Bossé, Guillermo de Velasco, Philip J. Stephens, Craig Norton
Publikováno v:
British Journal of Cancer
Background The genomic landscape of primary clear cell renal cell carcinoma (ccRCC) has been well described. However, little is known about cohort genomic alterations (GA) landscape in ccRCC metastases, or how it compares to primary tumours in aggreg